Biotech Startups

Pixelgen develops DNA-based visualization technology for cell-surface proteomics, enabling nanoscale spatial analysis of immune cell proteins for precision medicine and translational research. The company's Proximity Network Assay platform supports applications in immunology, hematology, and cell therapy diagnostics and therapeutics.

2 investors

PL BioScience develops human platelet-based cell culture media that promote cell growth, used in biotechnology research and cell culture applications. The company was founded in 2015 in the environment of RWTH Aachen University.

2 investors

Plantee develops renewable-based bio products and biocomposites from waste and by-product streams sourced from forestry, agriculture, and marine ecosystems to replace fossil inputs in consumer products. The company targets the emerging circular bioeconomy market in Canada.

2 investors

Plantik develops plant engineering technologies that use genomic data and biotechnology to tap into underexplored genetic variation and create climate-resilient crops, with an initial focus on thermotolerant plants that withstand heat stress. It targets challenges around harvest yield, seed availability, and food security.

2 investors

Pleno develops a genomic testing instrument platform designed to make multiomics testing faster, lower-cost, and higher-plex than existing methods like NGS, PCR, and microarrays. It targets clinical genomics applications such as oncology to support AI-driven precision medicine.

2 investors

Plex Research develops AI based on search engine algorithms to help biopharmaceutical companies analyze data for drug discovery and scientific research. It serves pharmaceutical and biotechnology companies working to turn data into better medicines.

2 investors

Pluto Bio provides a cloud-based, AI-native platform for multi-omics data analysis and program management, letting scientists organize experiments, run transcriptomics, proteomics, spatial, and single-cell analyses, and generate publication-ready visualizations without coding. It serves pharma and translational science teams, academic research labs, and CROs, and spun out of Harvard's Wyss Institute.

2 investors

Polaris Genomics is a Veteran-owned biotech startup mapping molecular biomarkers to develop objective, biologically-based diagnostics and novel therapeutics for mental health and neuropsychiatric conditions such as PTSD. It combines genomics and AI to advance precision mental health care.

2 investors

POLARISqb combines quantum computing, genetics, and molecular chemistry to design novel drugs for previously undruggable diseases. The company targets pharmaceutical development using advanced computational methods to accelerate drug discovery.

2 investors

Polymerize applies machine learning to polymer formulation, modeling the relationships between material structure, processing conditions, and resulting properties. The software suggests candidate formulations so teams run fewer physical experiments. It is used by R&D groups in materials and chemicals companies developing new products.

2 investors

Possible Ventures is a venture capital firm that invests in mission-driven teams building companies with frontier technology. Its portfolio spans areas such as biotech, materials, fusion energy, and space exploration.

2 investors

ProtaGene provides molecular bioanalytical services for gene therapy development, specializing in biodistribution studies, transgene expression assessment, and vector shedding analysis to support preclinical safety evaluation and clinical development of viral vector-based therapies.

2 investors

Precede Biosciences develops a blood-based diagnostic platform that profiles gene expression from cell-free DNA to reveal disease biology at the transcriptional level for drug developers and clinical trials. The platform enables non-invasive patient selection and longitudinal tracking of disease mechanisms in oncology and other therapeutic areas.

2 investors

Precigen is a biopharmaceutical company developing gene and cell therapies, including PAPZIMEOS (zopapogene imadenovec-drba), an FDA-approved immunotherapy for adults with recurrent respiratory papillomatosis. The company focuses on immuno-oncology and immunotherapy treatments delivered via subcutaneous injection.

2 investors

PreComb is a Swiss biotech company developing its proprietary 3DTwin technology, which combines automated drug testing on patient-derived tumor twins with AI-guided data analysis and response prediction. The technology is designed for use in the clinic to support evidence-based, personalized treatment decisions in oncology.

2 investors

Predictably Human is developing NoMore, an adaptive drug delivery device paired with a personalized digital companion, aimed at patients with mental health conditions, addiction, and other complex disorders. The system is intended to support an ecosystem of digital products and services around treatment.

2 investors

Prelude Therapeutics is a precision oncology company developing cancer treatments for areas of high unmet need, with a pipeline including selective KAT6A degraders and mutant-selective JAK2V617F JH2 inhibitors. It also applies targeted protein degradation expertise to develop next-generation degrader antibody conjugates (DACs).

2 investors

PreludeDx develops precision diagnostic tests for breast cancer to help physicians make informed treatment decisions and improve patient outcomes. The company serves oncologists, breast surgeons, and pathologists requiring molecular diagnostics for DCIS and other breast cancer subtypes.

2 investors

Prenostics develops a blood test to detect the earliest stages of cancer (stages 0-2), earlier than current methods, aiming to enable curative treatment. Its initial clinical targets are women at elevated risk of ovarian cancer and people with indeterminate lung nodules.

2 investors

Preventive.bio focuses on preventing disease before birth. The page provides no further detail about its products, technology, or customers.

2 investors

Prime Discoveries develops multiplex PCR diagnostic panels that detect pathogens and antimicrobial-resistance genes across areas such as respiratory infection, sepsis, gastrointestinal illness, STIs, tropical fevers, and biosurveillance. Its panels serve clinical diagnostics, hospital infection control, public-health surveillance, pharmaceutical QC, and biodefense applications.

2 investors

PrismBio develops biotech-derived colorants grown through fermentation of photosynthetic bacteria for use in food, beverages, and consumer products. The company produces natural, customizable pigments as sustainable alternatives to petrochemical-based dyes.

2 investors

ProFound Therapeutics discovers and develops therapeutic candidates by analyzing the expanded human proteome, identifying novel proteins from previously uncharacterized genetic sequences that can serve as drug targets for cancer, immune disorders, and metabolic diseases.

2 investors

Prolynx develops ultra-long-acting therapeutics for obesity and metabolic diseases such as type 2 diabetes, using a hydrogel-based microsphere platform with tunable release linker chemistry to control drug release over extended dosing intervals. Its lead program, PLX-821 (semaglutide), and broader pipeline of dual/triple agonists, amylin-based, and combination therapies are built on this half-life extension delivery architecture.

2 investors